Media Articles Related to Anturane (Sulfinpyrazone)
An Update on Managing Gout (With an Occasional Side of Steak?)
Source: Medscape Rheumatology Headlines [2015.11.20]
Dr N. Lawrence Edwards discusses the latest in gout management and related highlights from the 2015 American College of Rheumatology Annual Meeting.
Could Old Gout Drug Offer New CV Benefits? (CME/CE)
Source: MedPage Today Cardiovascular [2015.11.20]
(MedPage Today) -- Colchicine use was associated with fewer cardiovascular events and lower all-cause mortality
Did Michelangelo Have Gout?
Source: Medscape Orthopaedics Headlines [2015.11.18]
Did Michelangelo have gout? If so, the disease seems to have had little impact on his artistic productivity.
Journal of Clinical Rheumatology
Source: MedicineNet Amyloidosis Specialty [2015.11.18]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/18/2015 12:00:00 AM
Astrazeneca presents positive update on lesinurad renal data in gout patients
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.11.12]
AstraZeneca has announced positive subanalysis data of the Phase III lesinurad studies (CLEAR1, CLEAR2 and CRYSTAL) for the treatment of hyperuricemia associated with gout, in combination with a...
Published Studies Related to Anturane (Sulfinpyrazone)
The effect of sulfinpyrazone on treadmill exercise-induced angina pectoris. 
Suspecting that platelet thromboemboli could play a role in the pathogenesis of myocardial ischemia, we have done a random-order, double-blind, crossover study of the effect of the platelet-active drug sulfinpyrazone on treadmill exercise-induced angina pectoris in 30 men with coronary artery disease.
Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. [2000.12]
BACKGROUND: Management of cyclosporine (CsA)-associated hyperuricemia in heart transplantation (HT) is difficult. Because of the myelotoxicity of combined allopurinol and azathioprine, we tested sulfinpyrazone... However, this drug reduced CsA levels, thus the risk of rejection is present.
Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits. [1998.08]
The protective activity of the phenylbutazone derivative, sulfinpyrazone on retinal lesions has been assessed in rabbits with severe streptozotocin-induced diabetes. Sulfinpyrazone (8 mg kg-1 per day per os) was administered in diabetic animals in two different experimental procedures: for 135 days in a preventive approach (beginning on the day of initial hyperglicaemia); and for 30 days in a therapeutic approach (beginning on the day of appearance of severe retinal damage)...
Acute renal failure due to sulfinpyrazone. [1998.05]
A case of sulfinpyrazone-associated acute renal failure is reported. Sulfinpyrazone can cause reversible acute renal failure from acute tubular necrosis in patients with volume depletion.The patients at risk for acute renal failure due to sulfinpyrazone are those who have intravascular volume depletion as sensed by the kidneys.
Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. [1991.06.15]
We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis... A relatively high rate of complications, particularly mild gastrointestinal bleeding, was noted in patients on aspirin/sulfinpyrazone that could not be predicted on the basis of pre-treatment hemostatic test results.